NASDAQ · Financial Statements

First Tracks Biotherapeutics, Inc. (TRAX) Revenue, Earnings & Financial Statements

$43.57 NASDAQ: TRAX Market Cap $1.83B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

First Tracks Biotherapeutics, Inc. most recently reported annual revenue of $0, a net loss of $166.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

First Tracks Biotherapeutics, Inc.: net profit was positive in 0 of 3 reported years; the most recent year shows a net loss of $166.0M.

Income Statement — 3 Years (USD millions)

Metric202320242025
Revenue$0$0$0
Operating Expenses$118.0M$181.0M$179.0M
Operating Profit−$118.0M−$181.0M−$179.0M
Other Income$12.0M$17.0M$13.0M
Interest$0$0$0
Depreciation$2.0M$2.0M$2.0M
Profit Before Tax−$106.0M−$164.0M−$166.0M
Tax rate (%)0.0%0.0%0.0%
Net Profit−$106.0M−$164.0M−$166.0M
EPS−$3.05$0.00$0.00

Quarterly Results — Last 5 Quarters (USD millions)

MetricMar '25Jun '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0
Operating Expenses$51.0M$46.0M$53.0M$35.0M$33.0M
Operating Profit−$51.0M−$46.0M−$53.0M−$35.0M−$33.0M
Interest$0$0$0$0$0
Profit Before Tax−$47.0M−$42.0M−$50.0M−$33.0M−$31.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%
Net Profit−$47.0M−$42.0M−$50.0M−$33.0M−$31.0M
EPS−$1.36−$1.22−$1.45−$0.94−$0.88

Over the 3 years reported for First Tracks Biotherapeutics, Inc., borrowings decreased from $18.0M in 2023 to $14.0M in 2025, cash stood at $238.0M in the latest year, shareholders' equity was $288.0M, current assets covered current liabilities 10.19 times.

Balance Sheet — 3 Years (USD millions)

Metric202320242025
Total Assets$444.0M$442.0M$331.0M
Current Assets$399.0M$390.0M$316.0M
Cash$36.0M$123.0M$238.0M
Inventory$0$0$0
Receivables$0$0$0
Fixed Assets$18.0M$16.0M$14.0M
Capital Work in Progress$0$0$0
Investments$382.0M$298.0M$73.0M
Other Assets$0$0$0
Total Liabilities$34.0M$50.0M$43.0M
Current Liabilities$18.0M$36.0M$31.0M
Borrowings$18.0M$16.0M$14.0M
Other Liabilities$16.0M$34.0M$29.0M
Equity$411.0M$391.0M$288.0M
Reserves$410.0M$392.0M$287.0M

For First Tracks Biotherapeutics, Inc., operating cash flow was positive in 0 of 3 reported years; free cash flow in the latest year was negative at $143.0M; free cash flow was positive in 0 of 3 years.

Cash Flow Statement — 3 Years (USD millions)

Metric202320242025
Operating Cash Flow−$93.0M−$126.0M−$143.0M
Investing Cash Flow$144.0M$95.0M$228.0M
Financing Cash Flow$0$0$30.0M
Net Cash Flow−$35.0M$87.0M$115.0M
Free Cash Flow−$94.0M−$126.0M−$143.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.13
EV / EBITDA-2.47
FCF Yield-6.41%
Quick Ratio10.19
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

First Tracks Biotherapeutics, Inc. (TRAX) financials — frequently asked questions

What is First Tracks Biotherapeutics, Inc.'s annual revenue?

First Tracks Biotherapeutics, Inc. (TRAX) reported annual revenue of $0 in its most recent fiscal year.

What is First Tracks Biotherapeutics, Inc.'s net profit?

First Tracks Biotherapeutics, Inc. (TRAX) reported a net loss of $166.0M in its most recent fiscal year.

What is TRAX EV/EBITDA?

First Tracks Biotherapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -2.47. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
TRAX Overview TRAX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.